SMS Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 02, 2025, titled "Vizag plant receives WHO Geneva prequalification approval".
SMSPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts more than Nifty Microcap 250 and 1.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
SMS Pharmaceuticals has received prequalification approval from WHO Geneva for its Unit VII manufacturing facility in Visakhapatnam (capacity 3,000 KL). This approval enhances the company's global regulatory standing and enables it to expand its presence in the global market for Anti-Retroviral (ARV) Active Pharmaceutical Ingredients (APIs). The company, established in 1990, operates two facilities — Hyderabad (120 KL) and Vizag (3,000 KL) — and serves customers in over 70 countries. Management stated this milestone reflects strong compliance with stringent international regulatory standards and reinforces the company's reputation for quality and global competitiveness.
Positive for the company — WHO prequalification is a key requirement for supplying ARV APIs to global health programmes (e.g., Global Fund, UNICEF, USAID), potentially opening up significant new export revenue opportunities and strengthening long-term growth prospects.